Chemotherapy News and Research

Latest Chemotherapy News and Research

PNP reaches several major objectives in cancer therapeutic product development

PNP Therapeutics, Inc. — an early-stage Birmingham-based biopharmaceutical company created from research conducted at Southern Research Institute and The University of Alabama at Birmingham — today announced that several major objectives have been reached in the development of its therapeutic technology platform and proprietary products for the treatment of cancer.

11 Mar 2011

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC).

11 Mar 2011

SAP may serve as effective nanomaterial to prevent prostate cancer spread

When prostate cancer stem cells were enclosed in self-assembling nanomaterials made of peptides, the SAP stopped cancer stem cell colony formation and also stopped the division of cancer cells in laboratory cultures.

11 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

CTI announces final pixantrone clinical trial design for treatment of DLBCL

Cell Therapeutics, Inc. today announced the final clinical trial design of a randomized pivotal trial of pixantrone for the treatment of diffuse large B-cell lymphoma following discussions with the U.S. Food and Drug Administration's Division of Hematologic Products.

10 Mar 2011

Salmonella may serve as valuable tool to fight against cancer

University of Minnesota researchers are using salmonella - the bacteria commonly transmitted through food that sickens thousands of U.S. residents each year - to do what was once unthinkable: help people.

10 Mar 2011

Israel grants patent to Kamada's Transferrin for use in Pharmaceutical Compositions

Kamada, a biopharmaceutical company developing, manufacturing and marketing specialty life-saving therapeutics, announced today it has received an Israeli Patent for its Ultrapure Transferrin to be used in Pharmaceutical Compositions.

10 Mar 2011

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

ERYtech Pharma announces the early completion of the enrollment and safety follow-up a Phase II clinical trial for GRASPA. This open-labeled trial introduced GRASPA in a first-line treatment for Acute Lymphoblastic Leukemia in patients older than 55 years.

9 Mar 2011

Study supports DNA mismatch repair test for bowel cancer

Bowel cancer patients whose tumors contain defects in specific DNA repair systems are much less likely to experience tumour recurrence post surgery, results from a major clinical study have demonstrated.

9 Mar 2011

Overall survival rate for ovarian cancer have increased over last 30 years

Survival from ovarian cancer has almost doubled over the last 30 years according to new figures from Cancer Research UK released today.

9 Mar 2011

Chemist discover new strategy to process certain drugs

A prolific University of Missouri chemist has discovered a quicker and easier method for pharmaceutical companies to make certain drugs.

9 Mar 2011

Chemotherapy drugs also kill malaria parasite

A group of researchers from EPFL's Global Health Institute (GHI) and Inserm (Institut National de la Sant- et de la Recherche M-dicale, the French government agency for biomedical research) has discovered that a class of chemotherapy drugs originally designed to inhibit key signaling pathways in cancer cells also kills the parasite that causes malaria. The discovery could quickly open up a whole new strategy for combating this deadly disease.

9 Mar 2011

Study finds increase in oral tongue cancer incidence in young US white females

A UNC study released this week in the Journal of Clinical Oncology finds an increasing incidence of squamous cell carcinoma of the oral tongue in young white females in the United States over the last three decades.

9 Mar 2011

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Plexxikon today announced that it has treated the first patient in a Phase 2 clinical trial in Hodgkin lymphoma with PLX3397. This novel agent is an oral, selective inhibitor that down-modulates two key cell types that are thought to mediate the progression of Hodgkin lymphoma tumors — macrophages and mast cells.

8 Mar 2011

$100 million in grants for medical research announced

More than $100 million in grants was announced this Tuesday for an ambitious research project that will try to find what makes cancer so hard to beat. This project received $21.3 million from the National Health and Medical Research Council grants.

8 Mar 2011

New insight into malaria

A group of researchers from EPFL's Global Health Institute and Inserm has discovered that a class of chemotherapy drugs originally designed to inhibit key signaling pathways in cancer cells also kills the parasite that causes malaria.

8 Mar 2011

New review shows difficulty in delivering high-quality cancer care

A shortage of oncologists and rising costs of chemotherapy and radiation therapies and imaging tests, are making delivering quality cancer care increasingly difficult, according to a new review by researchers at RTI International and Eli Lilly and Company.

8 Mar 2011

UCSF's new pharmacy to focus on direct patient care

Although it won't be obvious to UCSF Medical Center patients, behind the scenes a family of giant robots now counts and processes their medications. With a new automated hospital pharmacy, believed to be the nation's most comprehensive, UCSF is using robotic technology and electronics to prepare and track medications with the goal of improving patient safety.

8 Mar 2011

New discovery can provide insight into lung cancer

A discovery at University of Colorado Cancer Center shows testing lung cancer on a molecular level can produce new insights into this deadly disease.

8 Mar 2011

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.

7 Mar 2011